The future of anticoagulation

Paul P. Dobesh, Karissa Kim, Zachary Stacy

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Anticoagulant agents, such as unfractionated heparin and warfarin, have been in use for roughly 50 years. Over the past decade, injectable agents such as low-molecular-weight heparins, pentasaccharide, and direct thrombin inhibitors have been major advances in preventing and treating thrombosis. Despite these somewhat recent additions, there is still enormous potential to improve on the pharmacokinetic and pharmacodynamic properties of these agents, as well as improve patient outcomes. There are currently a large number of anticoagulant agents (injectable and oral) that could be available for use in the next several years. Many of these new agents have unique mechanisms that may provide practitioners with anticoagulant alternatives. This review gives a detailed analysis of the anticoagulant agents that may add to our armamentarium in the management of thrombosis.

Original languageEnglish (US)
Pages (from-to)370-384
Number of pages15
JournalJournal of Pharmacy Practice
Issue number5
StatePublished - Oct 2004
Externally publishedYes


  • Anticoagulants
  • Future
  • Thrombin
  • Ximelagatran

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'The future of anticoagulation'. Together they form a unique fingerprint.

Cite this